Cyclopharm Limited · ASX:CYC

Cyclopharm — Shareholder Meeting (May 2012)

32 slides from Cyclopharm's shareholder meeting presentation, May 24, 2012

  1. Slide 1: Cyclopharm Limited Annual General Meeting

    For personal use only Cyclopharm Limited Annual General Meeting 24 May 2012

  2. Slide 2: Disclaimer

    Disclaimer For personal use only Certain views expressed here contain information derived from publicly available sources that have not been independently verified. The presentation includes certain statements, estimates and projections with respect to the anticipated future financial performance of

  3. Slide 3: Agenda

    Agenda For personal use only Chairman’s Address Managing Director’s Review Question Time Business Close 3

  4. Slide 4: Chairman's Address

    For personal use only Chairman’s Address Vanda Gould 4

  5. Slide 5: Managing Director's Review

    For personal use only Managing Director’s Review James McBrayer 5

  6. Slide 6: Mission & Values

    Mission & Values For personal use only Strategy To be the recognised world leader in pulmonary imaging and the Australasian manufacturing leader of radiopharmaceuticals used in Positron Emission Tomography Mission Cyclopharm’s mission is to enable nuclear medicine clinicians with the ability to impr

  7. Slide 7: Cyclopharm business: Three business units

    Cyclopharm business Three business units For personal use only Cyclopharm ‐ helping save lives everyday! Technegas Radiopharmaceuticals Diagnostic Imaging Established in 1986 continues to Establishment of PET central Developing centres that provide generate revenue, profits and strong pharmacies to

  8. Slide 8: Highlights – 2011

    Highlights – 2011 For personal use only Delivering on our Strategy  Technegas business strong and consistent with Patient Administration Sets (PAS) units increasing 4% over previous year  United States FDA approval of Special Protocol Assessment during Q1 2011. Investigational New Drug Application

  9. Slide 9: Segmental Overview

    For personal use only Segmental Overview 9

  10. Slide 10: Technegas Global footprint

    Technegas Global footprint For personal use only • Technegas is sold in 55 countries across the world • Over 2,600,000 patient studies since 1986 • 170,000 patient studies conducted in 2011 • 1,240 Technegas generators sold globally Asia Americas, Pacific, 18% 21% • Expanding operations in North Ame

  11. Slide 11: Molecular Imaging - Positron Emission Tomography (PET)

    Molecular Imaging ‐ Positron Emission Tomography (PET) For personal use only PET is the future of Nuclear Medicine. Positron Emission Tomography allows physicians to differentiate between healthy and active diseased tissue. PET is primarily used in the detection of cancer but rapid growth in . other

  12. Slide 12: AGCNCO Competitive Neutrality Complaints Office

    AGCNCO Australian Government Competitive Neutrality Complaints Office For personal use only Competitive Neutrality Requires Government Enterprises to : • Charge prices that fully reflect costs • Pay, or include an allowance for, government taxes and ANSTO Fails to charges such as goods and Services

  13. Slide 13: Diagnostic Imaging

    Diagnostic Imaging For personal use only PET • Joint venture with: X‐Ray • 50% Alfred Health Solutions CT • 30% Macquarie University • 20% CycloPet • Comprehensive suite of imaging Cardiac CT modalities MRI • State of the art research platform Ultra‐ • Inpatient and outpatient services sound • Found

  14. Slide 14: Imaging Techniques

    Imaging Techniques For personal use only X-ray , CT Ultrasound . MRI MR Spectroscopy fMRI SPECT PET with CT CT= Computed tomography; MRI= Magnetic Resonance Imaging; fMRI- Functional MRI; 14 SPECT- Single Photon Emission Computed Tomography; PET – Positron Emission Tomography

  15. Slide 15: 2011 Financials

    For personal use only 2011 Financials 15

  16. Slide 16: Profit & Loss

    Profit & Loss For personal use only Foundation strong while investing for the future 2011 2010 Technegas Division • TG revenue consistent with Sales Revenue $9,465,455 $9,442,763 prior year with PAS volumes Profit before tax and Finance Costs $1,699,883 $1,845,650 4% higher Molecular Imaging • $1,9

  17. Slide 17: Sales revenue - Segmental Review (Technegas)

    Sales revenue ‐ Segmental Review For personal use only Technegas sales volumes continue to rise Technegas Revenue in $m Patient Administration Sets (PAS) 7.4 7.3 • PAS revenue flat from 2010 • PAS volumes up 4% from 2010 1.3 1.2 2010 2011 Technegas Generators PAS TG Generators • Both revenue and vol

  18. Slide 18: Sales revenue - Segmental Review (Molecular Imaging)

    Sales revenue ‐ Segmental Review For personal use only Molecular Imaging ‐ MUH link provides advantage Cyclopet • First 12 months of operations recording revenues at $849k • Strong competition from public sector cyclotron facilities • Lag in indication approval/funding compared to the rest of the wo

  19. Slide 19: Sales revenue: Half year comparison

    Sales revenue Half year comparison For personal use only  Historical Trend – strong second half results 8.0 0.51 6.0 #039;m 4.0 6.78 0.34 6.19 6.19 2.0 4.32 3.27 3.28 0.0 2009 H1 2009 H2 2010 H1 2010 H2 2011 H1 2011 H2 Technegas CPET 19

  20. Slide 20: Foreign Exchange

    Foreign Exchange For personal use only European Volumes Historically Seasonal CYC European Sales € 2,500 2,000 1,500 1,000 500 0 REV € '000 • CYC has not historically taken a foreign exchange position • Given current Eurozone instability, a short‐term hedge may be considered appropriate to cover re

  21. Slide 21: Balance Sheet

    Balance Sheet For personal use only  Improved Net Asset Position 31‐Dec‐11 31‐Dec‐10 Current Assets $8,687,324 $8,409,488 • Renewed $5.1m bank Non‐current Assets $12,605,889 $13,732,411 facility Total Assets $21,293,213 $22,141,899 • Net Capital Raising of Current Liabilities $6,575,368 $7,978,925

  22. Slide 22: Operating Cash flow

    Operating Cash flow For personal use only  Technegas cash flows offsetting start‐up costs • Operating Activities for 31‐Dec‐11 31‐Dec‐10 2011 @ positive inflow of Operating Activities $563,627 ‐$90,960 $564k Investing Activities ‐$753,230 ‐$6,218,108 • Significant cash was Financing Activities $697

  23. Slide 23: Business Outlook 2012

    For personal use only Business Outlook 2012 23

  24. Slide 24: Business Outlook: Technegas

    Business Outlook Technegas For personal use only New Drug Application (NDA) • Investigational New Drug Application submitted and approved Q4 2011 • Clinical trial commencement to start within weeks • Expected trial completion mid 2014 with commercialisation in 2015 New Indications for Technegas • Co

  25. Slide 25: Business Opportunity: Technegas USA Market Potential

    Business Opportunity Technegas For personal use only USA Market Potential • USA is the largest single nuclear medicine market in the world • Potential of up to 300,000 patient studies per annum • Potential $23m in cumulative sales and $9.0m EBITDA in the first 2 years after receiving marketing autho

  26. Slide 26: Business Outlook: PET Radiopharmaceuticals

    Business Outlook PET Radiopharmaceuticals For personal use only Macquarie University Hospital (MUH) • Continue to expand our FDG customer base in NSW • Focus on new product development • Develop clinical research opportunities Expansion Opportunities • Evaluate expansion opportunities within the Aus

  27. Slide 27: Business Outlook: Diagnostic Imaging - MMI

    Business Outlook Diagnostic Imaging ‐ MMI For personal use only • Macquarie University has taken 30% equity position in the venture • No cash requirement budgeted in 2012 • Implement breast clinic services in collaboration with Macquarie University Hospital • Expand Cancer Care Clinic visibility and

  28. Slide 28: Conclusion

    For personal use only Conclusion 28

  29. Slide 29: Cyclopharm business

    Cyclopharm business For personal use only Cyclopharm ‐ helping save lives everyday! Technegas Radiopharmaceuticals Diagnostic Imaging Established in 1986 continues to Establishment of PET central Developing centres that provide generate revenue, profits and strong pharmacies to produce PET services

  30. Slide 30: Cyclopharm Business Summary

    Cyclopharm Business Summary For personal use only Technegas Radiopharmaceuticals Diagnostic Imaging • Consistent performer • Long term view remains • New Shareholder optimistic providing additional • Continued growth in funding existing markets • Productivity Commission report received in April 2012

  31. Slide 31: Question Time & Business

    For personal use only Question Time & Business 31

  32. Slide 32: Proxy Summary

    Proxy Summary For personal use only Resolution Business For* Against Abstain Proxy’s discretion 1 Remuneration Report 148,345,840 118,633 - 25,000 2 Re-election of Mr Gould 148,459,302 - 5,171 25,000 3 Renewal of share buy- 148,450,589 13,884 - 25,000 back capacity 4 Issue of shares under LTI 148,32

Cyclopharm — Shareholder Meeting (May 2012) on 6ix